SpringWorks Therapeutics Inc. (SWTX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
How Much Upside is Left in SpringWorks Therapeutics (SWTX)? Wall Street Analysts Think 77.9%
The mean of analysts' price targets for SpringWorks Therapeutics (SWTX) points to a 77.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
SpringWorks Therapeutics Recent Developments Move This To Speculative Buy (Upgrade)
Investment merits have increased materially since my last article with more support for its approved therapy and pipeline advancements. Ample liquidity supports its operations and pipeline development. Despite its potential SpringWorks carries significant risks for investors.
SpringWorks (SWTX) Q2 Earnings Beat, Ogsiveo Drives Revenues
SpringWorks (SWTX) reports better-than-expected second-quarter results. The newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.
SpringWorks Therapeutics: Rising On A Strong Post-Launch Quarter, Now Justified As A Buy
SWTX's market confidence has increased post-launch, with $40.2 million in product revenue and $19.5 million in collaboration revenue in the first quarter. Nirogacestat approval for desmoid tumors and potential approval for mirdametinib in 2025 position SWTX well for growth. SWTX's strong commercial execution and expanding product portfolio indicate the potential for profitability and market appreciation.
SpringWorks Therapeutics (SWTX) Reports Q2 Loss, Tops Revenue Estimates
SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $1.12. This compares to loss of $1.25 per share a year ago.
SpringWorks (SWTX) Rises More Than 40% in a Year: Here's Why
SpringWorks' (SWTX) Ogsiveo is the first drug approved by the FDA to treat desmoid tumors. The company's efforts to develop its pipeline candidate, mirdametinib, for treating NF1-PN also hold promise.
SpringWorks (SWTX) Completes NDA Submission for Mirdametinib
SpringWorks (SWTX) completes the submission of a new drug application for its MEK inhibitor, mirdametinib, for treating patients with neurofibromatosis type 1- associated plexiform neurofibromas.
